Spojené státy - angličtina - NLM (National Library of Medicine)

nephron pharmaceuticals corporation - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 0.25 mg in 2 ml - budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. limitations of use: - budesonide inhalation suspension is not indicated for the relief of acute bronchospasm. the use of budesonide inhalation suspension is contraindicated in the following conditions: - primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. - hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension [see warnings and precautions (5.3), description (11) and adverse reactions (6.2)]. risk summary there are no adequate well-controlled studies of budesonide inhalation suspension in pregnant women. however, there are published studies on the use of budesonide, the active ingredient in budesonide inhalation suspension, in pregnant women. in animal reproduction studies, budesonide, administered by the subcutaneous route, caused structur

Spojené státy - angličtina - NLM (National Library of Medicine)

dispensing solutions, inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 0.5 mg in 2 ml - budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. important limitations of use: - budesonide inhalation suspension is not indicated for the relief of acute bronchospasm. the use of budesonide inhalation suspension is contraindicated in the following conditions: - primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. - hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension [see warnings and precautions (5.3), description (11) and adverse reactions, post-marketing experience (6.2) ]. studies of pregnant women, have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy. the results from a large population-based prospective cohort epidemiological study reviewing data from three swedish registries covering approximately 99% of the pregnancies from 1995-1997 (ie, sw

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x) - budesonide 0.25 mg in 2 ml - budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. important limitations of use: - budesonide inhalation suspension is not indicated for the relief of acute bronchospasm. the use of budesonide inhalation suspension is contraindicated in the following conditions: - primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. - hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension [see warnings and precautions (5.3), description (11) and adverse reactions, post-marketing experience (6.2) ]. studies of pregnant women, have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy. the results from a large population-based prospective cohort epidemiological study reviewing data from three swedish registries covering approximately 99% of the pregnancies from 1995-1997 (ie, sw

Spojené státy - angličtina - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 ml - desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Spojené státy - angličtina - NLM (National Library of Medicine)

actavis mid atlantic llc, lincolnton, nc 28092 - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 ml - desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations. safety and effectiveness in pediatric patients have not been established. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of hpa axis suppression when they are treated with topical corticosteroids. they are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of cushing's syndrome while on treatment. adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. hpa axis suppression, cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracrania

Spojené státy - angličtina - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 g - desonide ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Spojené státy - angličtina - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 g - desonide cream, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide cream, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Spojené státy - angličtina - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 g - desonide ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Spojené státy - angličtina - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 ml - desonide lotion is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. desonide lotion is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Spojené státy - angličtina - NLM (National Library of Medicine)

physicians total care, inc. - desonide (unii: j280872d1o) (desonide - unii:j280872d1o) - desonide 0.5 mg in 1 g - desonide ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. it should not be used for longer than two weeks unless directed by a physician. desonide ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.